The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...
In this episode of The UroOnc Minute, host Adam B. Weiner, MD, speaks with Stephen J. Freedland, MD, about the role of diet and nutrition in prostate cancer risk and outcomes. The phase 2 study is ...
Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...
Dr. Shawn Zimberg and Dr. Dean Laganosky discuss the BioProtect Balloon Transplant System, a rectal spacer for use in prostate cancer radiation. Laganosky: The BioProtect rectal spacing device is a ...
The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures. Uncomplicated urinary tract infection is one of the most common indications for antimicrobial exposure in otherwise ...
"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.
Decision-making between ureteroscopy and shock wave lithotripsy involves evaluating clinical evidence, patient preferences, and procedural success rates. Shock wave lithotripsy is noninvasive but may ...
A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...
In this interview, Seth P. Lerner, MD, discusses current recommendations for managing patients during the BCG shortage, what the FDA is doing to resolve the problem, and a SWOG trial testing a new ...
In a retrospective study of almost 500 men, the use of hyaluronic acid filler for penile girth enhancement appeared safe with limited adverse events. Using the PhalloFILL system, a novel hyaluronic ...
Testosterone replacement therapy may not increase prostate cancer recurrence risk, but evidence remains inconclusive, necessitating individualized treatment plans. Bipolar androgen therapy (BAT) ...
Multiple investigational agents have been developed and are being studied. High-risk NMIBC is a resource-intensive entity, with a clinical hallmark being frequent recurrences and risk of progression, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback